Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of He… (NCT01104428) | Clinical Trial Compass
UnknownPhase 2
Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura
China256 participantsStarted 2009-11
Plain-language summary
Due to high incidence of renal damage by Hench-schonlein Purpura(HSP) is the key to affect prognosis, this project moves the research emphasis forward in line with the idea of "prevention of progress of disease", Which concerns on Traditional Chinese Medicine(TCM) clinical research scheme evaluation of HSP, evaluates the renal damage and disease recurrence as the end event, and comes to the evaluation through the comparative study that the vantage point of the scheme of syndrome differentiation and treatment in detoxification, cooling blood and removing blood stasis to the conventional treatments can reduce kidney damage and recurrence rate.
Who can participate
Age range
5 Years – 18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* To comply with the diagnostic standard of purpura in TCM and Hench-schonlein purpura in western medicine;
* To comply with the diagnostic standard of TCM syndrome differentiation;
* Age between 5 and 18;
* without similar herbal treatment a week before being included;
* Informed Consent Form is required to be singed.
Exclusion Criteria:
* Fall short of the diagnostic standard of purpura in TCM and Hench-schonlein purpura in western medicine;
* Fall short of the diagnostic standard of TCM syndrome differentiation;
* Older then 18 years or younger then 5years;
* Take similar herbal treatment within a week before being included;
* Can not take the drug according to the regulation or follow-up on time
* Patients combine serious primary disease in respiratory、gastrointestinal、hemopoietic、renal，or psychosis,or pestilence;
* Allergic to drugs of this research or others;
* human subject of other clinical research in the nearly tow weeks.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
whether endpoint such as renal damage or disease recurrence appears in the participants.
Timeframe: 6 months
Trial details
NCT IDNCT01104428
SponsorLiaoning University of Traditional Chinese Medicine